<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01934725</url>
  </required_header>
  <id_info>
    <org_study_id>SECRETO</org_study_id>
    <nct_id>NCT01934725</nct_id>
  </id_info>
  <brief_title>Searching for Explanations for Cryptogenic Stroke in the Young: Revealing the Etiology, Triggers, and Outcome</brief_title>
  <acronym>SECRETO</acronym>
  <official_title>Searching for Explanations for Cryptogenic Stroke in the Young: Revealing the Etiology, Triggers, and Outcome (SECRETO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SECRETO Study Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Finnish Medical Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Academy of Finland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helsinki and Uusimaa Hospital District</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital District of Southwest Finland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pirkanmaa Hospital District</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital District of North Ostrobothnia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital District of Northern Savo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>SECRETO Study Consortium</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      BACKGROUND: In industrialized countries a considerable and increasing proportion of strokes&#xD;
      occur at younger ages. Stroke at young age causes marked disability at worst and thus&#xD;
      long-standing socioeconomic consequences and exposes survivors for 4-fold risk of premature&#xD;
      death compared with background population. Up to 50% of young patients with ischemic stroke&#xD;
      remain without definitive etiology for their disease despite extensive modern diagnostic&#xD;
      work-up (i.e. cryptogenic stroke). The group of cryptogenic strokes includes those with&#xD;
      patent foramen ovale (PFO) or other abnormalities in the atrial septum in the heart as the&#xD;
      only or concomitant finding. Population prevalence of PFO is high, 25%, and the mechanisms&#xD;
      how PFO would be associated causally with ischemic stroke remain to be clarified. Moreover,&#xD;
      there are only scarce data on clinical outcome, long-term risk of new vascular events, and&#xD;
      prevention of such events in these patients.&#xD;
&#xD;
      DESIGN: Searching for Explanations for Cryptogenic Stroke in the Young: Revealing the&#xD;
      Etiology, Triggers, and Outcome (SECRETO) is an international prospective multicenter&#xD;
      case-control study of young adults (age 18-49) presenting with an imaging-positive first-ever&#xD;
      ischemic stroke of undetermined etiology (aim N=2000). Patients are included after&#xD;
      standardized diagnostic procedures (brain MRI, imaging of intracranial and extracranial&#xD;
      vessels, cardiac imaging, and screening for coagulopathies) and age- and sex-matched to&#xD;
      healthy controls in a 1:1 fashion. Up to 45 study sites worldwide will be needed to recruit&#xD;
      the planned participant population during a 3-year period. Neurovascular imaging and&#xD;
      echocardiography studies, and ECGs will be read centrally.&#xD;
&#xD;
      AIMS: SECRETO involves five principal fields of investigation: (1) Stroke triggers and&#xD;
      clinical risk factors; (2) Long-term prognosis (new vascular events, functional and&#xD;
      psychosocial outcomes); (3) Abnormalities of thrombosis and hemostasis; (4) Biomarkers of&#xD;
      e.g. inflammation, atherogenesis, endothelial function, thrombosis, platelet activation, and&#xD;
      hemodynamic stress to characterize postulated cryptogenic stroke mechanisms; and (5) genetic&#xD;
      study, including genome-wide association and candidate gene studies as well as&#xD;
      next-generation sequencing approach. All analyses consider cardiac functional and interatrial&#xD;
      structural properties as a possible mediator. Furthermore, SECRETO Family Study (substudy)&#xD;
      aims at collecting extensive family history of thrombotic events from informative patients&#xD;
      being screened for SECRETO main study and collect genetic samples from all consenting family&#xD;
      members for whole-genome sequencing.&#xD;
&#xD;
      SIGNIFICANCE: SECRETO will provide novel information on clinical and subclinical risk&#xD;
      factors, both transient and chronic, predisposing to cryptogenic ischemic stroke in young&#xD;
      adults. This study also reveals long-term prognosis of this understudied patient population&#xD;
      and may discover new genetic background underlying the disease mechanism and provide&#xD;
      potential targets for drug development.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2013</start_date>
  <completion_date type="Anticipated">December 2031</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Nonfatal or fatal recurrent ischemic cerebrovascular event</measure>
    <time_frame>10 years</time_frame>
    <description>Ischemic stroke or transient ischemic attack</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite of noncerebrovascular arterial or venous thrombotic events, or cerebral venous thrombosis</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death from any cause</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New-onset atrial fibrillation</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Modified Rankin Scale</measure>
    <time_frame>10 years</time_frame>
    <description>Functional outcome will be assessed with modified Rankin Scale at mandatory 3-month visit and at annual follow-up contacts from year 1 to year 10.</description>
  </other_outcome>
  <other_outcome>
    <measure>Vocational outcome</measure>
    <time_frame>10 years</time_frame>
    <description>Vocational status will be assessed at each follow-up contact with Poststroke Working Activity Questionnaire and a set of questions designed for the study.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cognitive outcome</measure>
    <time_frame>3 months</time_frame>
    <description>Cognition will be assessed at mandatory 3-month follow-up visit (Montreal Cognitive Assessment).</description>
  </other_outcome>
  <other_outcome>
    <measure>Anxiety and depression</measure>
    <time_frame>10 years</time_frame>
    <description>Poststroke anxiety and depression will be evaluated at 3-month visit, 1-year, 5-year, and 10-year follow-up contacts with Hospital Anxiety and Depression Scale.</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of life</measure>
    <time_frame>10 years</time_frame>
    <description>Quality of life will be assessed at 3-month visit, 1-year, 5-year, and 10-year follow-up contacts with EuroQol questionnaire.</description>
  </other_outcome>
  <other_outcome>
    <measure>Caregiver burden</measure>
    <time_frame>3 months</time_frame>
    <description>Poststroke burden to caregiver will be assessed at 3-month visit with Expanded Caregiver Strain Index Questionnaire.</description>
  </other_outcome>
  <other_outcome>
    <measure>Barthel Index</measure>
    <time_frame>10 years</time_frame>
    <description>Functional outcome will be assessed with Barthel Index at mandatory 3-month visit and at annual follow-up contacts from year 1 to year 10.</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Brain Infarction</condition>
  <condition>Ischemic Stroke</condition>
  <condition>Thrombosis</condition>
  <condition>Foramen Ovale, Patent</condition>
  <arm_group>
    <arm_group_label>Patients w/ cryptogenic ischemic stroke</arm_group_label>
    <description>Patients aged 15 to 49 years with unexplained first-ever ischemic stroke</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stroke-free control subjects</arm_group_label>
    <description>Stroke-free subjects age- and gender-matched to patients</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Patients at baseline:&#xD;
&#xD;
      4 x 2.7 mL sodium citrate tube, aliquoted in 10 x 300 µL cryovials; 1 x 5 mL PPACK sodium&#xD;
      citrate tube, aliquoted in 5 x 300 µL cryovials; 1 x 8 mL serum tube, aliquoted in 5 x 300 µL&#xD;
      cryovials; 1 x 9 mL EDTA tube #1, aliquoted in 10 x 300 µL cryovials; 1 x 9 mL EDTA tube #2,&#xD;
      full blood for DNA extraction.&#xD;
&#xD;
      Patients at 3-month visit (fasting): 4 x 2.7 mL sodium citrate tube, aliquoted in 10 x 300 µL&#xD;
      cryovials; 1 x 5 mL PPACK sodium citrate tube, aliquoted in 5 x 300 µL cryovials; 1 x 8 mL&#xD;
      serum tube, aliquoted in 5 x 300 µL cryovials; 1 x 9 mL EDTA tube, aliquoted in 10 x 300 µL&#xD;
      cryovials.&#xD;
&#xD;
      Control subjects:&#xD;
&#xD;
      4 x 2.7 mL sodium citrate tube, aliquoted in 10 x 300 µL cryovials; 1 x 5 mL PPACK sodium&#xD;
      citrate tube, aliquoted in 5 x 300 µL cryovials; 1 x 8 mL serum tube, aliquoted in 5 x 300 µL&#xD;
      cryovials; 1 x 9 mL EDTA tube #1, aliquoted in 10 x 300 µL cryovials; 1 x 9 mL EDTA tube #2,&#xD;
      full blood for DNA extraction.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        1. Patients aged 18 to 49 hospitalized due to first-ever imaging-positive ischemic stroke&#xD;
             of undetermined etiology;&#xD;
&#xD;
          2. Age-, gender- and race-ethnicity-matched stroke-free control subjects&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        PATIENTS:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 to 49 at stroke onset&#xD;
&#xD;
          2. Patient hospitalized due to first-ever imaging-positive ischemic stroke of&#xD;
             undetermined etiology after complete timely diagnostic testing.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Baseline mandatory tests not obtained in the first week following stroke onset,&#xD;
             including:&#xD;
&#xD;
               -  Brain MRI&#xD;
&#xD;
               -  Routine blood tests, including complete blood count, CRP, fasting glucose,&#xD;
                  creatinine, aPTT, INR, total cholesterol, LDL-cholesterol, HDL-cholesterol,&#xD;
                  HbA1C, hemoglobin electrophoresis in individuals of African origin&#xD;
&#xD;
          2. Other baseline mandatory tests not obtained within the first two weeks following&#xD;
             stroke onset, including:&#xD;
&#xD;
               -  Imaging of cervicocephalic arteries by CTA, MRA, or DSA&#xD;
&#xD;
               -  Transesophageal (highly recommended) or transthoracic echocardiography&#xD;
&#xD;
               -  24-hour Holter monitoring or continuous in-hospital ECG monitoring with automated&#xD;
                  arrhythmia detection for at least 24 hours&#xD;
&#xD;
               -  Screening for thrombophilia, including antiphospholipid antibodies and other&#xD;
                  coagulopathies (any abnormal finding must be retested at mandatory 3-month&#xD;
                  follow-up visit &gt;12 weeks from initial testing or &gt;4 weeks after cessation of&#xD;
                  anticoagulation at any later time point); mandatory tests include anticardiolipin&#xD;
                  antibodies, lupus anticoagulant, anti-β2-glycoprotein antibodies, factor V&#xD;
                  mutation (or aPC resistency ruled out), factor II mutation, homocysteine,&#xD;
                  antithrombin III, protein C, and protein S&#xD;
&#xD;
          3. No evidence of current brain ischemia&#xD;
&#xD;
          4. Current stroke due to cerebral venous thrombosis or as a complication of subarachnoid&#xD;
             hemorrhage, angiography, or cardiac surgery&#xD;
&#xD;
          5. Patient otherwise not eligible for the study or adherent for follow-up (eg&#xD;
             nonresident) or has concurrent disease affecting outcome (eg multiple sclerosis,&#xD;
             cancer)&#xD;
&#xD;
          6. Informed consent not obtained from the patient or a proxy.&#xD;
&#xD;
        CONTROL SUBJECTS:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 to 49 years&#xD;
&#xD;
          2. Absence of prior ischemic stroke as ascertained using the Questionnaire for Verifying&#xD;
             Stroke-Free Status&#xD;
&#xD;
        Exclusion Criterion:&#xD;
&#xD;
        1. Informed consent not obtained&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jukka Putaala, A/Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven Kittner, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jukka Putaala, A/Prof.</last_name>
    <phone>+35894711</phone>
    <email>jukka.putaala@hus.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Turgut Tatlisumak, Prof.</last_name>
    <phone>+35894711</phone>
    <email>Turgut.Tatlisumak@neuro.gu.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tartu University Hospital</name>
      <address>
        <city>Tartu</city>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janika Kõrv, MD, PhD</last_name>
      <email>Janika.Korv@kliinikum.ee</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>FI-00029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jukka Putaala, MD, PhD, MSc</last_name>
      <phone>+35894711</phone>
      <email>jukka.putaala@hus.fi</email>
    </contact>
    <investigator>
      <last_name>Sami Curtze, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Strbian, MD, PhD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Gordin, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mika Lehto, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juha Sinisalo, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tiina Sairanen, MD, PhD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jukka Putaala, MD, PhD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Per-Henrik Groop, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas Martinez-Majander, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kuopio University Hospital</name>
      <address>
        <city>Kuopio</city>
        <zip>70029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pekka Jäkälä, MD, PhD</last_name>
      <email>pekka.jakala@kuh.fi</email>
    </contact>
    <investigator>
      <last_name>Ossi Nerg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marja Hedman, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pekka Jäkälä, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oulu University Hospital</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juha Huhtakangas, MD, PhD</last_name>
      <email>juha.huhtakangas@ppshp.fi</email>
    </contact>
    <investigator>
      <last_name>Ulla Junttola, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antti Hakalahti, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juha Huhtakangas, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heikki Numminen, MD, PhD</last_name>
      <email>heikki.numminen@pshp.fi</email>
    </contact>
    <contact_backup>
      <last_name>Tomi Sarkanen, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Marko Virtanen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Essi Ryödi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Heikki Numminen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tomi Sarkanen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Turku University Central Hospital</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pauli Ylikotila, MD, PhD</last_name>
      <email>pauli.ylikotila@tyks.fi</email>
    </contact>
    <contact_backup>
      <last_name>Risto O. Roine, Prof.</last_name>
      <email>risto.roine@tyks.fi</email>
    </contact_backup>
    <investigator>
      <last_name>Riikka Lautamäki, A/Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antti Saraste, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pauli Ylikotila, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Risto O. Roine, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ernst-Moritz-Arndt University Medicine</name>
      <address>
        <city>Greifswald</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bettina von Sarnowski, MD, PhD</last_name>
      <email>bvsarnow@uni-greifswald.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>&quot;Attikon&quot; Hospital, University of Athens, School of Medicine</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georgios Tsivgoulis, MD, PhD</last_name>
      <email>tsivgoulisgiorg@yahoo.gr</email>
    </contact>
    <investigator>
      <last_name>Georgios Papadimitropoulos, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Georgios Tsivgoulis, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Brescia</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Pezzini, MD, PhD</last_name>
      <email>ale_pezzini@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Alessandro Pezzini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arcispedale S. Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marialuisa Zedde, MD, PhD</last_name>
      <email>Marialuisa.Zedde@asmn.re.it</email>
    </contact>
    <investigator>
      <last_name>Marialuisa Zedde, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vilnius University Hospital Santariskiu klinikos</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dalius Jatuzis, Prof.</last_name>
      <email>Dalius.Jatuzis@santa.lt</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Radboud University Nijmegen Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank-Erik de Leeuw, Prof.</last_name>
      <email>FrankErik.deLeeuw@radboudumc.nl</email>
    </contact>
    <investigator>
      <last_name>Frank-Erik de Leeuw, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrike Waje-Andreassen, Prof.</last_name>
      <email>uwan@helse-bergen.no</email>
    </contact>
    <investigator>
      <last_name>Halvor Naess, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anette Fromm, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sahrai Saeed, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ulrike Waje-Andreassen, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eva Gerdts, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Maria</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catarina A. Fonseca, MD, PhD, MPH</last_name>
      <email>catarinagfonseca@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>José M. Ferro, MD, PhD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Catarina A. Fonseca, MD, PhD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabel Amorim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ana Almeida, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Torrecárdenas University Hospital</name>
      <address>
        <city>Almería</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Martínez Sánchez, MD, PhD</last_name>
      <email>patrindalo@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petra Redfors, MD, PhD</last_name>
      <email>petra.redfors@vgregion.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istanbul University Istanbul Faculty of Medecine</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nilufer Yesilot Barlas, MD, PhD</last_name>
      <email>niluferyes@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Ali Elitok, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nilufer Yesilot Barlas, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Esme Ekizoglu Turgut, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peterborough City Hospital</name>
      <address>
        <city>Peterborough</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Radim Licenik, MD</last_name>
      <email>radim.licenik@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Stoke University Hospital</name>
      <address>
        <city>Stoke-on-Trent</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phillip Ferdinand, MD</last_name>
      <email>Phillip.Ferdinand@uhnm.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Estonia</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Lithuania</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Switzerland</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.secretostudy.net</url>
    <description>Study website</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 29, 2013</study_first_submitted>
  <study_first_submitted_qc>August 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2013</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>SECRETO Study Consortium</investigator_affiliation>
    <investigator_full_name>Jukka Putaala</investigator_full_name>
    <investigator_title>Associate Prof., MD, PhD, MSc</investigator_title>
  </responsible_party>
  <keyword>Ischemic Stroke</keyword>
  <keyword>Brain Infarction</keyword>
  <keyword>Patent Foramen Ovale</keyword>
  <keyword>Stroke in the Young</keyword>
  <keyword>Myocardial Infarction</keyword>
  <keyword>Cerebral Venous Thrombosis</keyword>
  <keyword>Pulmonary Embolism</keyword>
  <keyword>Deep Vein Thrombosis</keyword>
  <keyword>Subarachnoid Hemorrhage</keyword>
  <keyword>Prognosis</keyword>
  <keyword>Databases, Genetic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Brain Infarction</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Foramen Ovale, Patent</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

